Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 15/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10432751 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL10432710 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL10432216 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL26382105 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL12280207 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL10459031 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL12280226 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| SCHEMBL29430167 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL2418621 | 0.99 | AHCY (0.97) | AHCYADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL2412642 | 0.99 | AHCY (0.97) | AHCYADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627333-A1 | COMBINATION TREATMENT OF CANCER | Agency For Science, Technology And Research (SG) | 2013-08-21 | — | — | EP | claimed |
| US-20130210024-A1 | COMBINATION TREATMENT OF CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-08-15 | — | — | US | claimed |
| WO-2012050532-A1 | COMBINATION TREATMENT OF CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-19 | — | — | WO | claimed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | claimed |
| EP-0368640-A2 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-16 | — | — | EP | claimed |
| WO-2019185849-A1 | REGENERATION OF PLANTS IN THE PRESENCE OF INHIBITORS OF THE HISTONE METHYLTRANSFERASE EZH2 | KWS SAAT SE & Co. KGaA (DE) | 2019-10-03 | — | — | WO | disclosed |
| EP-3545756-A1 | REGENERATION OF PLANTS IN THE PRESENCE OF INHIBITORS OF THE HISTONE METHYLTRANSFERASE EZH2 | KWS SAAT SE & Co. KGaA (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-2646441-B1 | CARBOCYCLE-SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | EPIZYME INC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2627333-A1 | COMBINATION TREATMENT OF CANCER | Agency For Science, Technology And Research (SG) | 2013-08-21 | — | — | EP | disclosed |
| US-20130210024-A1 | COMBINATION TREATMENT OF CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-08-15 | — | — | US | disclosed |
| WO-2012050532-A1 | COMBINATION TREATMENT OF CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-19 | — | — | WO | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | AHCY 4001/4885ADORA2A 4784/4885ADORA2B 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.